‘Statistically Significant’ Changes

‘Statistically Significant’ Changes
While all participants saw their mental abilities decline over the course of the study, the group on the highest dose of BAN2401 showed significantly less disease progression than the placebo group on a range of cognitive tests.

The biggest relative reductions were seen on a test called the ADAS-cog, a set of 11 tasks that patients complete. The tasks measure deficits in memory, language, attention, and other mental abilities. It includes things like remembering words on a list, drawing figures, and following directions.

The 161 patients on the highest dose of the drug had about 47% less decline in their test scores, compared with 247 patients who were getting a placebo medication. That difference was statistically significant. The same group alo showed about 30% less decline than the placebo group on a different scale, the Alzheimer’s Disease Composite Score, or ADCOMS test.